SUGGESTED TIMETABLE FOR INITIAL AND SUBSEQUENT CLEARANCE MEASUREMENTS4
The following table is meant as a guide for assessing adequacy of the PD prescription based upon KDOQI recommendations. Depending on patient status, more frequent monitoring may be necessary with subsequent prescription adjustment.
The PET may be repeated if any or all of the following occur:
- Unexplained decrease in drain volume
- Persistent fluid overload/increase in BP
- Decrease in peritoneal solute clearance
- Increased need for hypertonic exchanges despite fluid/sodium restriction
- Unexplained uremic symptoms
| MEASUREMENT | FREQUENCY |
|---|---|
| Peritoneal Kt/Vurea | Baseline within first month, then every 4 months (or as needed if clinical change warrants) |
| Renal Kt/Vurea (only if urine volume is >100 mL/day and residual kidney clearance is being considered as part of the patient’s total weekly solute clearance goal) | Baseline at first month, then every 2 months (or sooner if clinical change warrants) |
| PET | Baseline at 4–8 weeks (then as needed if clinical change warrants)* |
* Recommend modified PET with 4.25% dextrose as follow-up